Tyler Bloomer, MD
Interventional Cardiology · Fort Worth, TXNPI 1306104765
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,158 of the $5,213 with a category attached, or 79.8%. 16 manufacturers reported payments, led by Medtronic at 39.1% of the total. That places this record below the midpoint for interventional cardiology clinicians in TX, where the typical reported total is $9,094.
Across 112 payments — averaging $46.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abbott$2K
- Edwards Lifesciences$314
- Abiomed$255
- Pfizer$166
- Novartis$154
- plus $654 from 10 others
Across 5 payments — averaging $49,223 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$246K
What the payments were for
- Travel & lodging$1,05520%
- Food & beverage$4,15880%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 49 | $2,038 |
| Abbott | 20 | $1,633 |
| Edwards Lifesciences | 3 | $314 |
| Abiomed | 4 | $255 |
| Pfizer | 8 | $166 |
| Novartis | 9 | $154 |
| E.r. Squibb & Sons, L.L.C. | 6 | $143 |
| AstraZeneca | 2 | $136 |
| Boston Scientific | 1 | $123 |
| Getinge USA Sales, LLC | 2 | $76 |
| Johnson & Johnson(2 entities) | 3 | $76 |
| Shockwave Medical, Inc | 1 | $37 |
| ZOLL Circulation Inc | 1 | $19 |
| Amgen | 1 | $18 |
| Heartflow, Inc. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRICLIP$985
- CoreValve Evolut$590
- Impella$180
- COREVALVE EVOLUT R$164
- MitraClip$145
- BRILINTA$125
- GENERAL CATHETER$123
- SAPIEN 3 Ultra RESILIA$108
How this compares
$5,213 in reported general payments places this provider in the 30th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 219 | $241,173 |
| JardianceEmpagliflozin | 133 | $122,971 |
| Repatha SureclickEvolocumab | 71 | $55,652 |
| XareltoRivaroxaban | 59 | $47,273 |
| EntrestoSacubitril/Valsartan | 21 | $28,789 |
| Praluent PenAlirocumab | 16 | $8,556 |
| Rosuvastatin Calcium | 337 | $5,156 |
| CrestorRosuvastatin Calcium | 11 | $4,256 |
| Metoprolol Succinate | 309 | $4,222 |
| Atorvastatin Calcium | 164 | $1,431 |
| ClopidogrelClopidogrel Bisulfate | 93 | $1,278 |
| Carvedilol | 124 | $1,027 |
| Amlodipine Besylate | 154 | $1,020 |
| Nifedipine ErNifedipine | 31 | $1,002 |
| Potassium Chloride | 38 | $822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $166 | $241,173219 claims |
| Johnson & JohnsonXarelto | $76 | $47,27359 claims |
| NovartisEntresto | $154 | $28,78921 claims |
| AstraZenecaCrestor | $136 | $4,25611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Fort Worth
- Elizabeth HolperFort Worth$206K
- Amir MalikFort Worth$136K
- Sukesh BurjonroppaFort Worth$130K
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.